{"prompt": "['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', '8.3', 'Day 0 Infusion (Arm 2 - PDT with HPPH)', '27', '8.4', 'Day 1 Treatment', '27', '8.5', 'About 1 Week Post Treatment', '28', '8.6', 'About 4 - 6 Weeks Post Treatment', '28', '8.7', 'About 12 - 16 Weeks Post Treatment', '28', '8.8', 'Post-Treatment Follow-Up Evaluations', '28', '8.9', 'Schedule of Procedures and Observations', '29', '8.10', 'Correlative Studies Sample Collection and Processing', '33', '8.10.1', 'Immune Monitoring for Isolation and Storage of Immune Cells', '33', '8.10.2', 'Photosensitizer (HPPH) and Biomarker (Serum Alkaline DNase) Levels in Serum', '33', '8.10.3', 'Diffuse reflectance optical spectroscopy', '34', '8.11', 'Pathology', '35', '8.12', 'Clinical', '35', '9', 'Efficacy Evaluations', '35', '9.1', 'Objective Tumor Response', '35', '9.2', 'Target Lesions', '35', '9.3', 'Evaluation of Response', '36', '10', 'Safety Evaluation', '37', '10.1', 'Adverse Events', '37', '10.1.1', 'Definition', '37', '10.1.1.1', 'Diagnosis Versus Signs and Symptoms', '37', '10.1.1.2 Adverse Events Occurring Secondary to Other Events', '37', '10.1.1.3 Abnormal Laboratory Values', '37', '10.1.1.4 Preexisting Medical Conditions (Baseline Conditions)', '38', '10.1.2', 'Grading and Relationship to Drug', '38', '10.1.3', 'Reporting Routine Adverse Events', '39', '10.2', 'Serious Adverse Events', '39', '10.2.1', 'Definition', '39', '10.2.2', 'Reporting Serious Adverse Events', '40', '10.3', 'Investigator Reporting: Notifying Photolitec LLC', '40', '10.4', 'Follow-Up for Serious Adverse Events', '40', '10.5', 'Unanticipated Problems', '40', '10.5.1', 'Definition', '40', '10.5.2', 'Reporting Unanticipated Problems', '41', '10.6', 'Safety Stopping Rule', '41', '10.7', 'FDA Reporting', '41', '11', 'data and safety monitoring board', '42', '12', 'Statistical Methodology', '42', '12.1', 'Justification for the statistical design and the non-inferiority margin', '43', '12.2', 'Sample Size Determination', '43', '12.3', 'Efficacy Analysis', '44', '12.4', 'Adverse Event', '44', '12.5', 'Interim Analysis and Criteria for Early Termination of the Study', '45', '13', 'Ethical and Regulatory Standards', '45', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 8 of 64']['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', '13.1', 'Ethical Principles', '45', '13.2', 'Informed Consent', '45', '14', 'Study Responsibilities', '46', '14.1', 'Data Collection', '46', '14.2', 'Maintenance of Study Documents', '46', '15', 'Administrative Rules', '47', '15.1', 'Revisions to the Protocol', '47', '15.2', 'Termination of the Study', '47', '15.3', 'Confidentiality', '47', '16', 'Appendices', '48', '17', 'References', '61', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 9 of 64']\n\n###\n\n", "completion": "END"}